罕见病知识库 RareSeen

亨廷顿舞蹈病

Huntington disease

定义 英文原文(暂无中文)

Huntington disease (HD) is a rare neurodegenerative disorder of the central nervous system characterized by unwanted choreatic movements, behavioral and psychiatric disturbances and dementia.

别名

亨廷顿舞蹈症

基本事实

遗传方式
常染色体显性
发病年龄
青少年期、成年期、儿童期、老年期
患病率
1-9 / 100 000(Greece)

相关基因 2

基因名称关联类型
HTThuntingtinDisease-causing germline mutation(s) (gain of function) in
SLC2A3solute carrier family 2 member 3Modifying germline mutation in

临床表型 53

极常见 99–80%3

  • 舞蹈样运动 HP:0002072
  • 反射亢进 HP:0001347
  • 智能衰退 HP:0001268

常见 79–30%31

  • 性欲异常 HP:0031845
  • 眼球运动异常 HP:0000496
  • 嗅觉异常 HP:0004408
  • 攻击性行为 HP:0000718
  • 焦虑不安 HP:0000713
  • 焦虑 HP:0000739
  • 情感淡漠 HP:0000741
  • 运动迟缓 HP:0002067
  • 思维过程异常缓慢 HP:0031843
  • 笨拙 HP:0002312
  • 强迫行为 HP:0000722
  • 妄想 HP:0000746
  • 抑郁 HP:0000716
  • 脱抑制 HP:0000734
  • 肌张力障碍 HP:0001332
  • 步态异常 HP:0001288
  • 步态异常 HP:0001288
  • 步态失平衡 HP:0002141
  • 泛发性肌无力 HP:0003324
  • 幻觉 HP:0000738
  • 愤怒 HP:0031473
  • 运动减少 HP:0002375
  • 不自主运动 HP:0004305
  • 易激惹 HP:0000737
  • 记忆障碍 HP:0002354
  • 肌阵挛 HP:0001336
  • 精细动作协调差 HP:0007010
  • 癫痫发作 HP:0001250
  • 言语表达困难 HP:0009088
  • 凝视 HP:0025401
  • 体重减轻 HP:0001824

偶见 29–5%19

  • 脑白质形态异常 HP:0002500
  • 胆固醇代谢异常 HP:0003107
  • 酗酒 HP:0030955
  • 巴彬斯基征 HP:0003487
  • 尾状核萎缩 HP:0002340
  • 脑萎缩 HP:0002059
  • 窒息发作 HP:0030842
  • 阵挛 HP:0002169
  • 体重指数下降 HP:0045082
  • 纹状体退行性变 HP:0040140
  • 日间睡眠增多 HP:0001262
  • 视空间结构认知障碍 HP:0010794
  • 行走不能 HP:0002540
  • 失眠 HP:0100785
  • 缄默症 HP:0002300
  • 口咽部吞咽困难 HP:0200136
  • 多食 HP:0002591
  • 强直 HP:0002063
  • 自杀意念 HP:0031589

近两年的全球研究 2,357L2

2024/10 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。

  • 2026-10综述
    Founder mutations in movement disorders: global distribution, molecular mechanisms, and clinical consequences-a scoping review
    Neurogenetics · DOI · Europe PMC
  • 2026-10综述开放获取
    Chaperone-mediated remodelling of mutant huntingtin
    Philosophical transactions of the Royal Society of London. Series B, B · DOI · Europe PMC
  • 2026-09
    Agentic AI for Clinical Outcomes Research, Population Health Management Analyses With Large Administrative Databases, and Generating Epidemiological Estimates of Diseases: Feasibility and Validation Study
    Journal of medical Internet research · DOI · Europe PMC
  • 2026-09
    Sex-dependent mild cardiac dysfunction and neurometabolic abnormalities in a model of Huntington's disease
    Disease models & mechanisms · DOI · Europe PMC
  • 2026-09综述开放获取
    Mechanistic Differences in Adult-Onset and Juvenile-Onset Huntington's Disease and the Potential Role of Neurodevelopment
    Cureus · DOI · Europe PMC
  • 2026-09
    Masking phosphatidylserine prevents neuronal loss in two distinct <i>Drosophila</i> models of neurodegeneration
    Proceedings of the National Academy of Sciences of the United States o · DOI · Europe PMC
  • 2026-09开放获取
    Huntingtin Aggregate-Responsive Autophagy Gene Circuit Mitigates Disease Pathology in R6/2 Mice
    Advanced science (Weinheim, Baden-Wurttemberg, Germany) · DOI · Europe PMC
  • 2026-09综述
    Uncovering hidden protein networks in Huntington's disease: implications for pathogenesis and therapy
    Molecular biology reports · DOI · Europe PMC
  • 2026-09开放获取
    Peripheral non-invasive focused ultrasound alleviates constipation by reducing gastrointestinal inflammation
    Experimental physiology · DOI · Europe PMC
  • 2026-09开放获取
    miR-196a reduces mutant Huntingtin aggregates by Rad23b-mediated degradation in Huntington's disease
    Journal of biomedical science · DOI · Europe PMC
  • 2026-09综述开放获取
    Fluid and Imaging Biomarkers in Huntington's Disease
    Current neurology and neuroscience reports · DOI · Europe PMC
  • 2026-09开放获取
    Special Issue "Advances in Neurodegenerative Diseases Research and Therapy-Third Edition"
    International journal of molecular sciences · DOI · Europe PMC
  • 2026-09综述
    The double-edged sentinel: cGAS-STING as a context-dependent regulator of microglial senescence and neuronal genotoxic stress in neurodegeneration
    Brain research bulletin · DOI · Europe PMC
  • 2026-09综述开放获取
    Current Landscape of Glycogen Synthase Kinase-3β PET Tracers: Progress, Limitations, and Perspectives-A Narrative Review
    Pharmaceuticals (Basel, Switzerland) · DOI · Europe PMC
  • 2026-09
    Visuospatial working memory in Huntington's disease: behavioural and structural brain correlates
    Journal of neurology, neurosurgery, and psychiatry · DOI · Europe PMC
  • 2026-09开放获取
    Decreased cerebrospinal fluid TNFRSF8 (sCD30) confirmed as a biomarker of Huntington's disease progression
    Journal of neurology · DOI · Europe PMC
  • 2026-09综述开放获取
    A systematic approach to MR spectroscopy of the brain: Indications, protocol, metabolites, and spectral analysis in neurologic diseases
    The neuroradiology journal · DOI · Europe PMC
  • 2026-09开放获取
    Proteomics in Ataxia Telangiectasia Fibroblasts Revealed Disease Hallmarks Recovered by ATM Variants
    International journal of molecular sciences · DOI · Europe PMC
  • 2026-09综述开放获取
    Nanopore Ultra-Long Sequencing for FSHD: From Molecular Diagnosis to Preimplantation Genetic Testing
    Genes · DOI · Europe PMC
  • 2026-09
    ZDHHC13 Is a Catalytically Deficient Protein S-Acyltransferase That Functions via a Noncanonical Mechanism
    ACS chemical biology · DOI · Europe PMC

境外已获批用于本病的药物 1L2

欧盟 0 项、美国 1 项。同一药物在两地各批一次的,会分别列出。

「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径,各有各的条件与费用。这一节能确定地告诉你的只有一件事:这个病在世界范围内已经有获得批准的药物,它叫什么名字。拿这个名字去问主治医生,是下一步最省力的做法。

药名一律保留英文原文,不作翻译——中国的药品通用名与英文名的音译经常不一致,译错会让人去找一个不存在的药。

尚未获批的在研药物(1 项)

这些药已被欧盟或美国的监管机构认定为罕见病用药(英文 orphan drug designation,中文行业里通称「孤儿药资格」——「孤儿」说的是这类药市场太小、没有厂商愿意认领,不是在说病人)。但这只是一种监管身份:意味着监管机构给予研发上的激励,不代表这个药已被证明有效,也不代表将来一定能上市,绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。

  • 2,4-dinitrophenol美国2019-02-11
    Treatment of Huntington disease
    官方记录

数据来自欧洲药品管理局(EMA)的药品与罕见病用药资格公开导出表,以及美国 FDA 的罕见病用药资格数据库(Orphan Drug Product Designation Database)。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。

在中国开展的临床试验 12L2

按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实,并与主治医生商量。

登记为可入组 3

  • 招募中NCT07326709
    A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
    III 期 · 干预性 · 2026/03/24Novartis Pharmaceuticals
    中国研究中心 5 个:Changsha、Chengdu、Guangzhou、Hangzhou、Wuhan
  • 招募中NCT07513844
    Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease
    不适用 · 干预性 · 2026/04/20First Affiliated Hospital of Fujian Medical University
    中国研究中心 1 个:Fuzhou
  • 尚未开始招募NCT07516899
    Mass Balance Study of [14C] LPM3770164 in Healthy Participants
    I 期 · 干预性 · 2026/04/30Luye Pharma Group Ltd.
    中国研究中心 1 个:Wuxi
其他状态的试验(9 项)
  • 状态未知NCT04244513
    Deep Brain Stimulation Treatment for Chorea in Huntington's Disease
    不适用 · 干预性 · 2020/02/01Beijing Municipal Administration of Hospitals
    中国研究中心 3 个:Beijing、Chengdu、Guangzhou
  • 状态未知NCT04071639
    Symptomatic Therapy for Patients With Huntington's Disease
    I 期 · 干预性 · 2020/03/12Second Affiliated Hospital, Zhejiang University, School of Medicine
    中国研究中心 1 个:Hangzhou
  • 已完成NCT05238701
    A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects
    I 期 · 干预性 · 2022/02/25Luye Pharma Group Ltd.
    中国研究中心 1 个:Shanghai
  • 已完成NCT06024265
    The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease
    早期 I 期 · 干预性 · 2023/04/04ExoRNA Bioscience
    中国研究中心 1 个:Guangzhou
  • 已完成NCT06216054
    Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects
    I 期 · 干预性 · 2023/12/19Luye Pharma Group Ltd.
    中国研究中心 1 个:Shanghai
  • 已完成NCT07601516
    Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China
    IV 期 · 干预性 · 2024/02/02Teva Branded Pharmaceutical Products R&D LLC
    中国研究中心 3 个:Beijing、Chengdu
  • 已完成NCT07344519
    The Safety and Tolerability Study With ER2001 Intravenous Injection Repetitive Treatment in Adults With Early Manifest Huntington's Disease.
    早期 I 期 · 干预性 · 2024/06/25ExoRNA Bioscience
    中国研究中心 1 个:Guangzhou
  • 已完成NCT06474650
    Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets
    I 期 · 干预性 · 2024/07/31Luye Pharma Group Ltd.
    中国研究中心 1 个:Shanghai
  • 进行中·不再招募NCT07339514
    A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease.
    I 期、II 期 · 干预性 · 2025/02/11ExoRNA Bioscience
    中国研究中心 3 个:Chengdu、Guangzhou

中国境外的在招试验 47L2

这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。

美国20法国12英国7德国6比利时5加拿大5荷兰5西班牙5意大利4波兰3葡萄牙3澳大利亚3新西兰3瑞士2另有 12 个国家/地区

CT.gov 报告命中 47 项,此处取回并展示最近的 15 项。

  • 尚未开始招募NCT07280650
    Feasibility and Acceptability of an LLM-based Chatbot for Family Caregivers: Evaluation Study
    不适用 · 干预性 · 2026/08University of Michigan
    美国
  • 招募中NCT07609108
    Pridopidine Phase 3 Study in Huntington's Disease
    III 期 · 干预性 · 2026/07/01Prilenia
    比利时、加拿大、捷克、法国、德国、意大利、荷兰、波兰 等 12 国
  • 招募中NCT07536061
    A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
    I 期 · 干预性 · 2026/05/12Sarepta Therapeutics, Inc.
    澳大利亚、新西兰、瑞士、英国
  • 招募中NCT07451613
    Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease
    I 期、II 期 · 干预性 · 2026/04/06Leslie Thompson
    美国
  • 尚未开始招募NCT07409597
    Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease
    不适用 · 干预性 · 2026/04/01University Hospital, Angers
    法国
  • 招募中NCT06634628
    iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009
    早期 I 期 · 干预性 · 2026/02/24CHDI Foundation, Inc.
    比利时
  • 尚未开始招募NCT07315984
    Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease
    观察性 · 2026/01/31BioSensics
    美国
  • 招募中NCT07378644
    Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
    II 期、III 期 · 干预性 · 2026/01/06Skyhawk Therapeutics, Inc.
    阿根廷、巴西、加拿大、智利、哥伦比亚、Georgia、德国、西班牙 等 9 国
  • 招募中NCT07253038
    Evaluation of Three Tests to Assess Social Cognition in Huntington Disease
    观察性 · 2025/12/01Region Skane
    瑞典
  • 招募中NCT06828471
    Social Cognition Training in Individuals With Huntington's Disease
    不适用 · 干预性 · 2025/11/15Rush University Medical Center
    美国
  • 招募中NCT06843252
    Home-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease
    不适用 · 干预性 · 2025/09/02The University of Texas Health Science Center at San Antonio
    美国
  • 招募中NCT06774443
    Hinting Task for Huntington's Disease
    观察性 · 2025/09/01University Medical Center Groningen
    荷兰
  • 尚未开始招募NCT06976983
    Transcranial Static Magnetic Stimulation (tSMS) in Huntington's Disease (HD)
    不适用 · 干预性 · 2025/09/01Neuromed IRCCS
  • 招募中NCT06807892
    Comparison of Two Cognitive-Motor Rehabilitation Approaches Via Exergames: a Study of Cognitive, Motor and Behavioral Functions in Huntington's Disease Patients
    不适用 · 干预性 · 2025/07/31University Hospital, Angers
    法国
  • 招募中NCT06546488
    Cognitive Assessment Tools for Huntington's Disease.
    观察性 · 2025/06/20Ohio State University
    美国

外部标识与链接

发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号

本页数据来源

  • 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
  • 中文病名:Orphanet 中文包,冻结于 2020-06-01
  • 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)